Ginsenoside Rb1 inhibits tube-like structure formation of endothelial cells by regulating pigment epithelium-derived factor through the oestrogen beta receptor

Author(s): Leung KW, Cheung LW, Pon YL, Wong RN, Mak NK, et al.

Abstract

Background and purpose: Angiogenesis is a crucial step in tumour growth and metastasis. Ginsenoside-Rb1 (Rb1), the major active constituent of ginseng, potently inhibits angiogenesis in vivo and in vitro. However, the underlying mechanism remains unknown. We hypothesized that the potent anti-angiogenic protein, pigment epithelium-derived factor (PEDF), is involved in regulating the anti-angiogenic effects of Rb1.

Experimental approaches: Rb1-induced PEDF was determined by real-time PCR and western blot analysis. The anti-angiogenic effects of Rb1 were demonstrated using endothelial cell tube formation assay. Competitive ligand-binding and reporter gene assays were employed to indicate the interaction between Rb1 and the oestrogen receptor (ER).

Key results: Rb1 significantly increased the transcription, protein expression and secretion of PEDF. Targeted inhibition of PEDF completely prevented Rb1-induced inhibition of endothelial tube formation, suggesting that the anti-angiogenic effect of Rb1 was PEDF specific. Interestingly, the activation of PEDF occurred via a genomic pathway of ERbeta. Competitive ligand-binding assays indicated that Rb1 is a specific agonist of ERbeta, but not ERalpha. Rb1 effectively recruited transcriptional activators and activated an oestrogen-responsive reporter gene. Furthermore, Rb1-mediated PEDF activation and the subsequent inhibition of tube formation were blocked by the ER antagonist ICI 182,780 or transfection of ERbeta siRNA, indicating ERbeta dependence.

Conclusions and implications: Here we show for the first time that the Rb1 suppressed the formation of endothelial tube-like structures through modulation of PEDF via ERbeta. These findings demonstrate a novel mechanism of the action of this ginsenoside that may have value in anti-cancer and anti-angiogenesis therapy.

Similar Articles

Interactions between traditional Chinese medicines and Western therapeutics

Author(s): Chan E, Tan M, Xin J, Sudarsanam S, Johnson DE

The Role of Coenzyme Q10 in Heart Failure

Author(s): Weant KA, Smith KM

The impact of coenzyme Q10 on systolic function in patients with chronic heart failure

Author(s): Sander S, Coleman CI, Patel AA, Kluger J, White CM

Studies on the constituents of Japanese and Chinese crude drugs

Author(s): Shibata S, Fujita M, Itokawa H, Tanaka O, Ishii T

Estrogen-like activity of ginsenoside Rg1 derived from Panax notoginseng

Author(s): Chan RY, Chen WF, Dong A, Guo D, Wong MS

[Chemical studies of crude drugs (1)

Author(s): Kitagawa I, Yoshikawa M, Yoshihara M, Hayashi T, Taniyama T

Apoptotic effects of ginsenoside Rh2 on human malignant melanoma A375-S2 cells

Author(s): Fei XF, Wang BX, Tashiro S, Li TJ, Ma JS, et al.

Effects of ginsenosides Rg3 and Rh2 on the proliferation of prostate cancer cells

Author(s): Kim HS, Lee EH, Ko SR, Choi KJ, Park JH, et al.

Rh2 synergistically enhances paclitaxel or mitoxantrone in prostate cancer models

Author(s): Xie X, Eberding A, Madera C, Fazli L, Jia W, et al.

Liquid chromatographic determination of less polar ginsenosides in processed ginseng

Author(s): Kwon SW, Han SB, Park IH, Kim JM, Park MK, et al.

[Determination of ginsenoside Rd and its metabolites in rat urine by LC-MS]

Author(s): Yang L, Xu SJ, Zeng X, Liu YM, Deng SG, et al.

Determination of Ginsenoside Rh2 in Enzyme Conversion by HPLC

Author(s): Jiang L, Zhao S, Ya L, Li J